NovaBay Pharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company dedicated to developing and commercializing novel anti‐infective products based on its proprietary Aganocide® technology platform. The company’s primary focus lies in addressing serious eye care conditions, wound care and disinfectant applications through small-molecule agents designed to mimic the body’s natural defense mechanisms against microbial pathogens.
Among its leading products, Avenova® is an FDA-cleared eyelid and lash hygiene treatment indicated for the management of chronic dry eye and blepharitis, offering a preservative‐free, sterile solution for daily eyelid hygiene. NeutroPhase® is an advanced wound irrigation and topical therapy designed to aid in the treatment of acute and chronic wounds, leveraging the antimicrobial properties of its active ingredient to promote faster healing. Additionally, ClearAqua™ serves as a broad‐spectrum disinfectant for medical devices and hard surfaces, meeting rigorous regulatory standards for environmental decontamination.
Founded in 2000 and headquartered in Emeryville, California, NovaBay has expanded its commercial reach across North America, Europe and selected Asian markets through strategic partnerships and distribution agreements. The company has established collaborative relationships with academic institutions and contract manufacturers to support its ongoing clinical programs and supply chain operations, while pursuing regulatory approvals in key markets worldwide.
Guided by an experienced leadership team led by Chief Executive Officer Jiande Wu, NovaBay continues to advance its pipeline through rigorous clinical validation and regulatory engagement. The company remains focused on leveraging its Aganocide® platform to address unmet medical needs, enhancing patient outcomes and driving long-term value in the anti‐infective therapeutics sector.
AI Generated. May Contain Errors.
